The 2026 CMS skin substitute reimbursement overhaul is not a routine Medicare update. It is a regulatory inflection point for outpatient and mobile wound care clinics billing for cellular and tissue-based products for diabetic foot ulcers and venous leg ulcers.

Medicare Part B spending skyrocketed to $10 billion for skin substitute reimbursement in 2024, and in 2026 CMS has set out to reel itself back in. To do so, it has implemented a new reimbursement scheme that it expects will contract wound care spending exponentially.  

But that will not be CMS’s only mode of damage control. If you are a wound care provider that bills Medicare Part B for advanced wound care, skin grafts, amniotic membrane products, fish skin grafts, or bioengineered skin substitutes, assume your utilization data is being reviewed.

CMS Reimbursement Reform Warn of Audit and Enforcement Risks

Effective January 1, 2026, the Centers for Medicare & Medicaid (CMS) reclassified most “wound care management” products as incident-to supplies under the Physician Fee Schedule. This means that the prior Average Sales Price reimbursement methodology is eliminated, and most products will be reimbursed under a single flat rate of $127.28/cm² per supplication, regardless of brand or product type.

This affects reimbursement for skin substitutes in three regulatory categories: (1) devices subject to premarket approval (PMA); (2) devices subject to 510(k) clearance; and (3) human cells, tissues and cellular and tissue-based products (HCT/Ps) regulated under Section 361 of the PHS Act. This impacts the following wound care utilization:

• Cellular and tissue-based product claims, including for Apligraf, Dermagraft, AmnioFix, Kerecis, and more

• Chronic wound treatment billing

• Diabetic foot ulcer skin substitute applications

• Venous leg ulcer advanced graft procedures

Flat per-square-centimeter reimbursement significantly compresses margins for every participant in the supply chain, including manufacturers, distributors, and health care providers. But the financial shift is only one layer of risk. Historically, when CMS restructures payment in a rapidly growing category, it is followed by:

• Medicare documentation audits

• MAC targeted probe and educate reviews

• Unified Program Integrity Contractor investigations

• OIG enforcement activity

• False Claims Act investigations by the DOJ

Accordingly, impeccable documentation of sustained medical necessity remains as crucial as ever as these enforcement agencies are laser focused on the wound care space in 2026.

Wound Care Enforcement Patterns Are Predictable

Recent wound care investigations have centered on allegations of:

• Medically unnecessary skin substitute applications

• Excessive repeat graft placement

• Anti-Kickback Statute violations involving product manufacturers

• Stark Law exposure tied to referral relationships

• False Claims Act liability based on documentation deficiencies

Each Medicare claim submitted for wound care treatment with skin substitute products represents a certification of compliance with federal law. If investigators determine that clinical documentation does not support medical necessity, repayment exposure can be extrapolated across years of claims. If financial arrangements with vendors raise inducement concerns, liability can escalate quickly.

Medicare, UnitedHealthcare, Humana, and BCBS Are Watching Wound Care

Although CMS initiated the reimbursement reform, commercial payers often mirror Medicare enforcement patterns. Like CMS, private payers increasingly use data analytics to identify outlier providers in skin substitute billing and skin graft utilization. If your clinic’s utilization of Apligraf, Dermagraft, AmnioFix, or Kerecis significantly exceeds regional benchmarks, you may already be on an internal watch list.

Payment Approval Is Not a Defense

Many wound care providers assume that because Medicare, UnitedHealthcare, Humana, or BCBS paid a claim, it was compliant. That assumption is dangerous. Payers routinely conduct post-payment audits. The Department of Justice regularly pursues False Claims Act cases years after reimbursement. Once a Civil Investigative Demand, OIG subpoena, or Medicare audit notice arrives, the focus shifts from prevention to defense.

The Time for Proactive Legal Review Is Now

The 2026 CMS reimbursement reform is a clear regulatory signal. If your clinic derives substantial revenue from skin substitute billing, diabetic foot ulcer treatment, or venous leg ulcer advanced wound care services, you are operating in a heightened enforcement environment.

Silence from regulators does not mean safety. It often means data analysis is underway.

If your wound care clinic bills Medicare, UnitedHealthcare, Humana, or BCBS for cellular and tissue-based products, now is the time to conduct a confidential legal compliance review.

Wound care compliance today requires more than coding accuracy. We can help evaluate wound care red flags before CMS or private payers do, including:

• High-frequency skin substitute applications

• Repeated graft placement at short intervals

• Large surface area billing  

• Modifier usage

• Frequency of skin substitute applications

• Revenue concentration in advanced wound care

• Templated wound care documentation

• Product selection trends

• Vendor consulting agreements tied to product usage

• Lack of internal wound care compliance audits

Once the audit begins, strategic options narrow quickly, but Health Law Alliance attorneys possess the experience to help your practices and documentation stand up to scrutiny.